SCHEMBL2391371

SCHEMBL2391371

NC(=O)C(O)c1ccccc1-c1ccccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CXCL8 P10145 1/20 0.41
PTPRC P08575 1/20 0.40
DPP4 P27487 1/20 0.39
IKBKB O14920 2/20 0.39
PARP1 P09874 1/20 0.38
SLC9A1 P19634 2/20 0.38
HSD17B10 Q99714 1/20 0.38
CASP1 P29466 1/20 0.38
SCN9A Q15858 1/20 0.38
KMT2A Q03164 2/20 0.37
ATM Q13315 1/20 0.37
GRM2 Q14416 1/20 0.37
AOC3 Q16853 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5065346 0.85 CASP1 (0.49) CXCL8CASP1AOC3ALDH1A1
SCHEMBL5065343 0.85 CASP1 (0.49) CXCL8CASP1AOC3ALDH1A1
SCHEMBL2390308 0.83 OPRL1 (0.38) KMT2AATMGRM2
SCHEMBL2393152 0.79 CES2 (0.46) PARP1SLC9A1KMT2AGRM2MEN1
SCHEMBL9890698 0.78 CASP1 (0.44) HSD17B10CASP1KMT2AALDH1A1NPSR1
SCHEMBL2393200 0.78 APP (0.43) PTPRCIKBKBSLC9A1
SCHEMBL2393198 0.78 APP (0.43) PTPRCIKBKBSLC9A1
SCHEMBL2391614 0.78 APP (0.43) PTPRCIKBKBSLC9A1
SCHEMBL2392699 0.78 BCAT2 (0.55) HSD17B10KMT2AMEN1ALDH1A1
SCHEMBL2395264 0.78 BCAT2 (0.55) HSD17B10KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US claimed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP claimed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US claimed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
WO-2010055911-A1 BIPHENYLACETAMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CXCL8 3300/4885PTPRC 3747/4885DPP4 3177/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CXCL8 3300/4885PTPRC 3747/4885DPP4 3177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.